Minerva Neurosciences | NERV - Выручка от реализации





Продажи Изменить Дата
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Adma Biologics USD 139.16M 4.94M 2025-12
ALKERMES USD 384.5M 9.7M 2025-12
Alterity Therapeutics Limited AUD 11.38K 10.23K 2022-12
AstraZeneca USD 15.5B 313M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Cipla INR 75.18B 710M 2025-12
Clal Biotechnology ILS 3.41M 2M 2022-12
Compugen USD 67.33M 65.44M 2025-12
CSL USD 8.33B 4.79B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
GlaxoSmithKline GBP 8.62B 73M 2025-12
Grifols EUR 2.34B 33.3M 2026-03
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
J&J USD 24.6B 610M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.86B 50M 2025-12
Novavax USD 147.14M 76.69M 2025-12
Pfizer USD 17.58B 880M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.3B 1.13B 2025-12
Takeda JPY 1.19T 80B 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12